Today: 4 April 2026
Subscribe
Browse Category

Stock Market 30 October 2025

Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump and Xi agreed to a one-year pause on new tariffs and rare-earth export curbs at the Busan summit. U.S. tariffs on China will drop to 47%, and China will resume buying U.S. soybeans. U.S. stock futures slipped Thursday after record highs, as Fed Chair Powell signaled caution on further rate cuts. Alphabet shares jumped on strong earnings, while Microsoft and Meta fell premarket.
30 October 2025
········
Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard reported Q3 2025 revenue of $8.60 billion, up 17% year-over-year, with net profit rising 20% to $3.96 billion. Shares traded near $570 in October, up about 8% year-to-date and close to their 52-week high. The company announced support for major US dollar stablecoins and is in late-stage talks to acquire crypto firm ZeroHash for up to $2 billion. About 80% of analysts rate the stock a buy.
30 October 2025
···
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Trump Touts “Tremendous” Soybean Deal with China – Farmers Cautious as Details Remain Vague

Trump Touts “Tremendous” Soybean Deal with China – Farmers Cautious as Details Remain Vague

President Trump announced China will buy large amounts of U.S. soybeans after meeting President Xi in Busan, but China offered no specific purchase commitments. U.S. soybean futures spiked, then fell 2.2% on uncertainty, settling near $10.80 per bushel Friday. Midwest farmers report billions lost from China’s near-total boycott. Analysts say China is still buying mostly Brazilian soybeans and warn U.S. tariffs remain unchanged.
30 October 2025
Citi Stuns Markets by Slashing Loan Rate – See What’s Next for Borrowers & Stocks

Citi Stuns Markets by Slashing Loan Rate – See What’s Next for Borrowers & Stocks

Citibank lowered its base lending rate to 7.00% from 7.25%, effective October 30, after the U.S. Federal Reserve cut its policy rate by 25 basis points to 3.75–4.00% on October 29. Citigroup shares fell 2.2% to $99 following the news, despite a strong year-to-date rally. Indian banks also trimmed lending rates in October, while the Reserve Bank of India kept its repo rate steady at 5.50%.
30 October 2025
··
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Novo Nordisk launched a hostile bid for Metsera on Oct. 30, 2025, offering up to $9 billion and topping Pfizer’s earlier $7.3 billion deal. Metsera shares jumped about 19% in premarket trading. The board called Novo’s offer “superior,” giving Pfizer four days to respond. A law firm began investigating whether the original Pfizer deal was fair to shareholders.
30 October 2025
····
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
GLE Stock Skyrockets 50%: Key Facts & What’s Next

GLE Stock Skyrockets 50%: Key Facts & What’s Next

Global Engine Group (Nasdaq: GLE) closed at $0.6526 on Oct. 29, then surged to nearly $1.00 in early Oct. 30 trading, a gain of about 50%. No news or filings explained the spike. GLE, a small Hong Kong tech firm, reported a sharp drop in revenue and a net loss for its latest fiscal year. The stock remains down 62% for 2025.
30 October 2025
·
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna shares closed at $299.12 on Oct 29, down 3% for the week, before rising to $303 in Oct 30 premarket trading. The company reported Q3 revenue of $69.7 billion and net income of $1.87 billion, beating forecasts and reaffirming its full-year outlook. Cigna launched a new pharmacy benefit model and Evernorth invested $3.5 billion in Shields Health. Analyst consensus remains bullish with a $370–$377 price target.
30 October 2025
···
Hot GDP Surprise Shatters Wall Street’s Rally – Stocks Slide on Fed Jitters (Sept 25, 2025)

Stock Market Rollercoaster: Tech Stocks Tumble After Trump-Xi Trade Truce & Fed’s Hawkish Signals

Trump and Xi agreed to cut some tariffs and resume Chinese soybean purchases, with China pausing rare-earths export curbs for a year. The U.S. Fed trimmed rates by 25 basis points but signaled caution on further cuts, boosting Treasury yields and the dollar. Mega-cap tech stocks slid after Meta’s earnings miss, while Alphabet and Nvidia surged. The Nasdaq hit a record high, but global equities were mixed amid rate and trade uncertainty.
30 October 2025
·······
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
Cambium Networks (CMBM) Stock Soars 377% on Starlink Tie-Up — Delisting Threats Loom

Cambium Networks (CMBM) Stock Soars 377% on Starlink Tie-Up — Delisting Threats Loom

Cambium Networks shares soared 377% to $2.95 on Oct 29 after announcing integration of its ONE Network platform with SpaceX’s Starlink. After-hours trading pushed the stock as high as $6.69. The rally followed recent Nasdaq delisting warnings and a CFO departure. Cambium’s market cap reached about $83 million, with analysts split on the outlook amid ongoing losses and volatile trading.
30 October 2025
··
VCI Global Stock Skyrockets 88% on AI-Crypto Token News: Microcap VCIG Rallies Afterhours

VCI Global Stock Skyrockets 88% on AI-Crypto Token News: Microcap VCIG Rallies Afterhours

VCIG shares jumped 87.8% in after-hours trading Oct. 29 to $3.38 after announcing its Smart Bridge unit will exclusively manage 1 billion XVIQ AI/GPU crypto tokens. The stock quickly fell back to around $1.80 by midday Oct. 30. VCIG recently guided for 2025 revenue of $47.3 million, up 70% year-over-year, and plans to launch a gold-backed crypto platform by Q2 2026. Market cap remains about $2–3 million.
30 October 2025
····
Inside Samsung: How the Tech Giant is Dominating Every Industry It Touches

Samsung Stock Soars on AI Chip Boom – Q3 Earnings Crush Estimates

Samsung Electronics shares jumped 3.6% to ₩104,100 on October 30, hitting a 52-week high after Q3 revenue reached ₩86.1 trillion and operating profit rose 32% to ₩12.2 trillion, fueled by record AI chip sales. The company plans major expansion of high-bandwidth memory production for AI servers. Samsung also launched its first Galaxy XR headset and announced a DRAM supply deal with OpenAI.
30 October 2025
····
Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown

Alphabet (GOOG) Hits Record High on Q3 Earnings Beat, AI Boom Fueling Rally

Alphabet shares jumped 6% to a record high near $270 on Oct. 30 after third-quarter earnings and revenue beat forecasts. Google’s ad revenue rose 12.6% to $74.2 billion, and cloud sales surged 34% to $15.16 billion. The company raised 2025 capital spending to as much as $93 billion for AI and cloud expansion. Wall Street remains bullish, with most analysts rating the stock a “Buy.”
30 October 2025
····
Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle Stock Craters After Tepid Q3 Earnings – What’s Next for CMG?

Chipotle shares plunged 18% pre-market Oct. 30 after management cut its 2025 same-store sales forecast to a low-single-digit decline, citing persistent macroeconomic pressures. Q3 revenue rose 7.5% to $3.0 billion, but same-store sales grew just 0.3% as customer traffic fell for the third straight quarter. Chipotle opened 84 new restaurants and repurchased $686.5 million in stock. The stock is down 34% year-to-date.
30 October 2025
···
Fiserv Earnings Miss Expectations, Shares Slide – What’s Next for the Fintech Giant?

Shock Selloff: Fiserv (FI) Stock Plunges 40% After ‘Shockingly Bad’ Q3, Major Shakeup Unveiled

Fiserv shares plunged about 42% to a 52-week low near $66 on Oct. 29, 2025, after missing Q3 estimates and slashing 2025 guidance. Adjusted EPS came in at $2.04 on $4.92 billion revenue, both well below forecasts. CEO Mike Lyons announced a turnaround plan and major leadership changes. The company will move its listing from NYSE to Nasdaq on Nov. 11.
30 October 2025
··
1 … 1,267 1,268 1,269 1,270 1,271 … 1,371

Stock Market Today

  • Pembroke VCT Boosts Capital with B Share Allotment as Market Liquidity Rises
    April 4, 2026, 7:59 AM EDT. Pembroke VCT plc, a UK-listed venture capital trust, has allotted 5.18 million new B Ordinary Shares, raising fresh capital for its high-growth portfolio. The shares, priced at 100.2p based on unaudited net asset value as of December 2025, will trade on the London Stock Exchange around April 9, 2026. This move increases total B shares to nearly 299 million, enhancing market liquidity. The company's diversified venture investments benefit from this capital injection amid persistent negative free cash flow and volatile results. Analyst consensus holds a 'Hold' rating with a £94 price target. Pembroke VCT operates under the UK's FCA rules, targeting smaller, growth-oriented firms and providing investors tax advantages linked to venture capital trusts (VCTs).
Go toTop